KRISTINE HICKMAN: Open Payments
NPI 1629515812 · SALISBURY, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,600 in 79 payments from 15 companies in 2025. Trend: 2023 $1,175 · 2024 $1,003 · 2025 $1,600
Food & beverage: $1,588Education: $12
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $295 |
| E.R. Squibb & Sons, L.L.C. | 15 | $267 |
| Lundbeck LLC | 14 | $221 |
| Otsuka America Pharmaceutical, Inc. | 7 | $199 |
| Vanda Pharmaceuticals Inc. | 4 | $190 |
| Alkermes, Inc. | 4 | $89 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $74 |
| Neurocrine BioSciences, Inc. | 2 | $49 |
| Teva Pharmaceuticals USA, Inc. | 3 | $48 |
| Janssen Pharmaceuticals, Inc | 2 | $42 |
Products named: REXULTI, COBENFY, VRAYLAR, FANAPT, ABILIFY ASIMTUFII, CAPLYTA, ARISTADA, MAVYRET.
Industry payments across MD — which companies pay providers there.
